Targets › IFIH1
1 program from 1 company in 3 trials: 3 Phase 1; Oncology; next expected readout Aug 2027.
Innate immune receptor which acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and pro-inflammatory cytokines. Its ligands include mRNA lacking 2'-O-methylation at their 5' cap and long double-stranded RNAs (>1 kb in length). (UniProt, Q9BYX4)
Open in Phaseline: the race on IFIH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Seqker Biosciences | Poly-ICLC (Hiltonol) TLR3 and RIG-I-like receptor agonist; immune adjuvant | IFIH1, DDX58 | Phase 1 | Solid Tumors; Follicular Lymphoma; Lymphocytic Leukemia | Aug 2027 |
Solid Tumors (1) Follicular Lymphoma (1) Lymphocytic Leukemia (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.